Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 24 July 2013 | By Alexander Gaffney, RAC,
Direct-to-consumer marketing is a topic of regular interest to regulators with the US Food and Drug Administration. At various times during the past several years, it has announced studies involving the use of composite scores in DTC advertising, the affect of DTC advertising on healthcare professionals, and corrective advertising resulting from improper DTC marketing.
Now it's making some substantial changes to a DTC study first approved in 2011, according to documents published on the Office of Management and Budget's (OMB) website.
The study, entitled "Experimental Study of Comparative Direct-to-Consumer (DTC) Advertising," was first approved in 2011 as a new collection of information. Under federal law, all such studies involving the public and a federal agency must first be approved by OMB's Office of Information and Regulatory Affairs (OIRA) and be subjected to a period of public comment.
In the past, companies have used that opportunity to comment to propose changes to the studies, including the addition of new questions, edits to existing questions, and the deletion of others that were deemed to be inappropriate.
But industry isn't the only one interested in getting more information out of the study, as OMB's documents show.
In a new information collection request submitted to OIRA on 23 July 2013, FDA-which did not submit a Federal Register notice regarding the request-explained that it's looking to "correlate four questions" from an existing health survey conducted by GfK with several of its own questions from the Comparative DTC survey.
FDA takes pains to note that it is "not requesting additional data" to be collected. Rather, it's looking to take information from the GfK survey and compare it against its own data "to explore some additional relationships"-information that should be of interest to almost anyone who works in the highly-regulated pharmaceutical marketing sector.
One of the questions pertains to how difficult a patient finds it to pay for his or her prescription medication, with answers ranging from "not at all difficult" all the way up to "extremely difficult."
Another question looks to see how consumers are actually looking for information, be it from in-person sources or online. Possible choices include doctors, healthcare professionals, family, friends, disease associations, pharmaceutical companies, newspapers, the Internet (specifically including social media), television, or not at all.
A third and related question polled participants on what resources they use to find health and wellness information on the Internet, including health-related websites like WebMD, social media, search engines, blogs, pharmaceutical company websites, hospital websites, government websites, and news websites.
Given the pressure from industry for FDA to release a guidance document on social media use by industry, this could be seen as yet another instance of the agency trying to determine how consumers use social media to find healthcare information.
A fourth and final question relates to consumer behavior on the internet, and asks if consumers have participated in any of the following activities:
The point of the entire exercise is to allow FDA to "look at the relationships between these variables and perceived risk, perceived benefit, behavioral intention, and source credibility from our existing questionnaire," it explained. "We expect that cost issues and information seeking tendencies will have direct effects on each of the dependent variables and that the relationship between these two independent variables and behavioral intention will be moderated by perceived benefit and risk."
OMB Notice
Tags: Benefit-risk, Benefit, DTC, Latest News, marketing, social media, risk
Regulatory Focus newsletters
All the biggest regulatory news and happenings.